F. Portela
Serviço de Gastrenterologia, Hospitais da Universidade de Coimbra, Coimbra, Portugal.
Texto Completo disponível apenas em PDF
Full text only available in PDF format
BIBLIOGRAFIA
]]>1. Stange EF. The case against using 5-aminosalicyclates in Crohn's disease: con. Inflamm Bowel Dis. 2005 Jun;11(6):613-5. [ Links ]
2. Hanauer SB. The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm Bowel Dis. 2005 Jun;11(6):609-12.
3. Summers RW, Switz DM, Sessions JT, et al. National co-operative Crohn's disease study group: results of drug treatment. Gastroenterology 1979;77:847-69.
4. Malchow H, Ewe K, Brandes JW, et al. European co-operative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
5. Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, doubleblind, placebo-controlled trial of the oral mesalamine (5- ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994;19:278-82.
6. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16- week trial. Gastroenterology 1993;104:1293-301.
7. Hanauer SB, Stro¨mberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-88
8. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001 Aug;121(2):255-60.
9. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89:2116-24.
10. Messori A, Brignola C, Trallori, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89:692-8.
]]> 11. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.12. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Library, Issue1 Chichester, Wiley, 2005.
13. Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology. 2000 Feb;118(2):264-73.
14. R Caprilli, M A Gassull, J C Escher, G Moser, P Munkholm, A Forbes, et al, for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55(Suppl I):i36-i58.
15. Greenberg GR, Feagan BG, Martin F, Martin F, Sutherland LR, Thomson AB, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836-841.
16. Thomsen OO, Cortot A, Jewel D, Wright JP, Winter T, Veloso FT, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998;339: 370-374.
17. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002;16:1509 - 1517.
18. Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979;77: 870-882
19. Travis SPL, Stange EF, Le´mann M, Resland TO, Chowers Y, Forbes A, et al, for the European Crohn's and Colitis Organisation (ECCO).European evidence based consensus on the diagnosis and management of Crohn's disease: current management Gut 2006; 55(Suppl I): 116-135.
20. Lemann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, et al, Groupe D'Etude Therapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005 Jun; 128 (7) : 1812-8.
]]> 21. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-987.22. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, Meyer zum Buschenfelde KH. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105: 367-372.
23. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 944-947.
24. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management Terapêutica Médicaof Crohn's disease. Gut 1995; 37: 674-678.
25. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975; 20: 721-726.
26. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar;130(3): 940-87.
27. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723-729.
28. Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004;127: 730-740.
29. Feagan BG, Rochon J, Fedorak RN, Irvine JE, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292-297.
30. Feagan BG, Fedorak RN, Irvine EJ, Sutherland L, Steinhart AH, Greenberg GR, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-1632.
]]> 31. Weinblatt ME. Methotrexate for chronic disease in adults. N Engl J Med 1995; 332: 330-331.32. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
33. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398- 1405.
34. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-413.
35. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608.
36. Travis SPL, Stange EF, Le´mann M, Resland TO, Chowers Y, Forbes A, et al, for the European Crohn's and Colitis Organisation (ECCO) European evidence based consensus on the diagnosis and management of Crohn's disease: current management Gut 2006;55(Suppl I):116-135.
37. Panaccione R, Fedorak RN, Aumais G, Bernstein CN, Bitton A, Croitoru K, et al. Canadian Association of Gastroenterology. Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. Can J Gastroenterol. 2004 Aug;18(8): 503-8.
38. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004 Feb 26; 350(9): 876-85.
39. Sartor RB. Episodic retreatment versus scheduled maintenance therapy of Crohn's disease with infliximab: not so far apart. Gastroenterology. 2004 Feb;126(2): 598-601.
40. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May;4(5):621-30.
]]> 41. FDA Board Document. Update on the TNF-alpha blocking agent; 2003. Available at: FDA Board Document. SAFETY OF TNF BLOCKING AGENTS. www.fda.gov/ohrms/dockets/ac/03/briefing/ 3930B1_01_B-TNF.Briefing.htm.42. S. Schreiber, M. Khaliq-Kareemi, I. Lawrance, S. Hanauer, J. McColm, R. Bloomfield, W. Sandborn. Certolizumab Pegol, a Humanized anti- TNF Pegylated FAB' Fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: A phase III study (PRECISE) Gut 2005; 54 (Suppl VII) A82
43. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb;130(2): 323-33; quiz 591.
44. J. Colombel, W.J. Sandborn, P. Rutgeerts, R.A. Enns, S.B. Hanauer, R. Panaccione, et al. Adalimumab maintains clinical response and remission in patients with active Crohn's disease: results of the CHARM trial. Gut 2006; 55 (Suppl V) A123
45. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-25.
46. Gert Van Assche, Marc Van Ranst, Raf Sciot, Bénédicte Dubois, Séverine Vermeire, Maja Noman, et al. Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease. N Engl J Med 2005; 353: 362-8.
]]>